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Abstract: 
Nausea and vomiting in early pregnancy is very common. The severest form, hyperemesis 
gravidarum,is important as mismanagement can lead to Wernicke’s encephalopathy, central 
pontine myelosis and death. 
There is a lack of high-quality evidence in the management of nausea and vomiting in early 
pregnancy and in the safety of the commonly used drugs, especially the reported side effects 
and their management. Pregnancies following bariatric surgery are becoming more frequent 
and care should be taken managing nausea and vomiting in this group since thiamine is 
primarily absorbed in the small intestine, and Wernicke’s encephalopathy has been described 
following some types of bariatric surgery. Severe cases of hyperemesis gravidarum warrant 
caution as Wernicke’s has been described following total parenteral nutrition,and it must be 
remembered that thiamine needs to be supplemented in this group. The etiology remains 
unknown and there is scope for research in this area. 
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Introduction: 
Nausea and vomiting may be the first symptom of pregnancy,usually peaks between 7 and 9 
weeks gestation, and the feeling of sickness and the inability to retain food and drink is common 
in early pregnancy and may be unique to humans(Gadsby et al, 1997).The symptoms even in 
its mildest form can still have a profound effect on the wellbeing of the woman, affecting her: 
physically, socially, psychologically and financially(Gadsby et al, 1997; Källén et al, 2003; 
Smith et al, 2000)and may have a negative impact on her health-related quality of life (Lacasse 
et al, 2008). These effects could extend to other members of the family.The management of 
the disease has an impact on health economics in term of bed occupancy, high readmission rate 
(Gadsby et al, 1997) and treatment costs. 
The symptoms may follow certain patterns, allowing some women to predict the timing of its 
occurrence(Gadsby et al, 1997) and to develop certain coping strategies, some of which are 
built on the women’s local community heritage acquired through the years (Thomson et al, 
2014). Not all affected women are capable of coping with the symptoms and some become 
severely affected to the degree that they become severely dehydrated or malnourished. 
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The treatment of nausea and vomiting of pregnancy is mainly symptomatic and supportive, and 
early treatment is more effective. In some cases, the disease can be protracted and may not 
respond to any medications or interventions(Gadsby et al, 1997).A wide range of interventions 
have been tried in the management of the condition with different claims of effectiveness and 
success, however, there is a lack of high-quality evidence to support any particular intervention 
(Matthews et al, 2010; Sanu and Lamont, 2011). 
The severe form of nausea and vomiting of pregnancy is termed Hyperemesis Gravidarum 
(HG). There is no consensus on or universal definition of HG. The International Statistical 
Classification of Disease and Related Health Problems defines HG as persistent and excessive 
vomiting starting before the end of the 22nd week of gestation, and in its severe form is 
associated with metabolic disturbances such as carbohydrate depletion, dehydration, or 
electrolyte imbalance (RCOG, 2016; WHO, 2007).HG is best defined as any combination of 
nausea, vomiting, dehydration, weight loss, or hospitalization for nausea and/or vomiting in 
pregnancy, in the absence of any other obvious cause for these complaints (Niemeijer et al, 
2014). 
An understanding of the condition is vital as mismanagement of these cases can lead to 
iatrogenic maternal deaths from Wernicke’s encephalopathy, which is characterized by 
diplopia, abnormal ocular movements, ataxia and confusion and/or central pontine myelosis, 
which is characterizedby spastic quadraparesis, pseudobulbar palsy and impaired 
consciousness (McClure et al, 2011). 
Despite being described many years ago, Wernicke’s encephalopathy secondary to HG is still 
being reported in the literature (Berdai et al, 2016), though, thankfully, mortalities are now 
rare. It has also been described following some types of bariatric surgery(Bohan et al, 2016), 
and should be kept in mind as pregnancy following bariatric surgery is becoming more 
common. 
Neglected cases and/or poor management can also lead to other significant morbidities, e.g. 
oesophageal tears, Venous Thrombo-Embolic disease (VTE), depression and placental 
abruption, especially for women with HG in the second trimester (Bolin et al, 2013). 
 
Incidence and associated risk factors: 
The reported incidence of nausea and vomiting in pregnancy varies from 35 to 91% (Einarson 
et al, 2013).Nausea is more frequent and causes most of the distress, and occurs in 99% of the 
women who have nausea and vomiting of pregnancy compared with vomiting, which occurs 
in 47% of the affected women (Gadsby et al, 2011), the same authors noticed that vomiting 
often signals the relief of symptoms. Nausea and vomiting may recur in subsequent pregnancies 
in as many as half to two thirds of the women, and the recurrence rate is even higher for HG 
(Gadsby et al, 2011; Trogstad et al, 2005).In contrast, the incidence of HG is about 11 to 15% 
(Einarson et al, 2013; Fiaschi et al, 2016; Vikanes et al, 2010)and is second only to preterm 
labour for admission to hospital (ACOG, 2004).Asian and black ethnicity appear to increase 
the risk of HG recurrence (Fiaschi et al, 2016). 
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Factors associated with nausea and vomiting of pregnancy include: lower maternal age, lower 
gravidity/parity, lower level of education, lower income, poorly-controlled diabetes, alcohol 
consumption,smoking, lower body mass index, and helicobacter pylori (Chan et al, 2011; Chou 
et al, 2008; Källén et al, 2003; Louik et al, 2006; Sandven et al, 2009). 
 
Etiology and pathophysiology: 
The etiology and pathogenesis of nausea and vomiting of pregnancy is unknown; however, 
there is likely to be an interaction of multiple factors including:hormonal, genetic, cultural and 
placental.Alterations in steroid hormone homeostasis, higher concentration of androstanediol 
glucuronide and decreased androstenedione concentrations have been observed in women with 
HG (Helseth et al, 2014). 
The symptoms of nausea and vomiting are usually worse with hydatidiform mole and multiple 
pregnancy, both of which are associated with higher concentrations of human chorionic 
gonadotrophin (hCG). The acidic isoforms of hCG may play a role in the etiology of HG 
(Jordan et al, 1999). Several studies have suggested a genetic link with HG (Fejzo et al, 2012; 
Fejzo et al, 2008; Zhang et al; 2011). 
Vomiting involves an interaction of neurophysiological connections to the chemoreceptor 
trigger zone, emetic centre and vestibular centre in the brainstem and medulla oblongata (Sanu 
andLamont, 2011). Further studies including functional Magnetic Resonance Imaging (MRI) 
may help clarify the pathophysiology. 
 
The effect of HG on the fetus: 
There is evidence that HG is associated with a higher female/male ratio of offspring, higher 
incidence of Low BirthWeight (LBW), Small for Gestational Age (SGA) and Pre-Term 
Birth(PTB) (Veenendaal et al, 2011). Little is known about the long-term health effects of 
babies born to mothers whose pregnancies were complicated by HG (Koren et al, 2014).There 
is no association between nausea and vomiting or HG and Apgar scores, the birth weight of the 
baby,birth defects, congenital anomalies, stillbirth or perinatal death (Gadsby et al, 2011; 
Veenendaal et al, 2011).On the other hand, more recent studies suggest that nausea and 
vomiting of pregnancy may actually be associated with favorable fetal outcome (Koren et al, 
2014; Vikanes et al, 2013) 
 
Diagnosis: 
The condition is usually self-limiting; however, in some women the symptoms may become 
protracted and difficult to manage. The start of the symptoms could be as early as 5 weeks 
gestation and it usually peaks between 7 and 9 weeks, and resolves by 22 weeks (Gadsby et al, 
2011). The symptoms can continue into the third trimester in about 23% of women(Einarson 
et al, 2013). 
It is important to remember that nausea and vomiting of pregnancy and HG are diagnoses of 
exclusion (RCOG, 2016).Therefore, affected women should be systematically reviewed to 
exclude other causes of nausea and vomiting, and the differential diagnosis for nausea and 
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vomiting in pregnancy could be exhausting and may include both medical and surgical causes, 
see table (1). 
 
Table (1) Showing the list of differential diagnoses for nausea and vomiting in early 
pregnancy. 
 
System Disease 
Pregnancy-related  Molar pregnancy 
Gestational trophoblastic disease 
Multiple pregnancy 
Threatened miscarriage 
Gastric Gastro-oesophageal reflux 
Peptic ulcer 
Gastritis 
Diaphragmatic hernia 
Gastric neoplasia 
Bowel Small bowel obstruction 
Gastroenteritis 
Appendicitis 
Bowel diseases e.g. Crohn's disease 
Liver and gallbladder  Acute Cholecystitis 
Gall stones 
Cholestasis of pregnancy 
Cholangitis 
Acute fatty liver 
Hepatitis 
Pancreatic Pancreatitis 
Uro-Renal Urinary infection 
Pyelonephritis 
Uremia 
Nephrolithiasis 
Endocrinological Poorly controlled Diabetes Mellitus 
Addison disease 
Hyperthyroidism 
Hyperparathyroidism 
Other rare causes: Torsion of an ovarian cyst 
Oesophageal pouch and stricture 
Reaction to medications 
Drug intoxication 
Drug abuse during pregnancy 
Food allergy 
Food poisoning 
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Eating disorders 
Vestibular disease 
Migraine 
Porphyria 
Increased intra-cranial pressure and brain tumors 
Pcychatric causes  
There is no widely accepted point at which nausea and vomiting in pregnancy becomes HG 
(O'Donnell et al, 2016) and there are no agreed diagnostic criteriafor HG and the symptoms 
are non-specific, but the following combinations of criteria are frequently described; however, 
evidence for the association between ketonuria and presence or severity of HG is lacking 
(Sandven et al, 2009): 
- Persistent vomiting in early pregnancy 
- Intractable vomiting occurring before 20 weeks of gestation 
- Recurrent vomiting that occurs more than three times per day 
- Recurrent vomiting that warrants hospital admission 
- Nauseaand vomiting with fluid and electrolyte disturbance 
- Nausea and vomiting with significant weight loss described as: 
o Loss greater than 3 kg or 
o Loss exceeding 5% of body weight  
- Nausea and vomiting with ketonuria unrelated to other causes 
- Hypersalivation 
Investigations: 
The investigations are decided by the circumstances of each individual case, but the following 
investigations are invariably requested, see table (2) 
 
Table (2) Shows the frequently-requested investigations in cases of nausea and vomiting 
of early pregnancy. 
 
Type of investigations  
Preliminary investigations Ultrasound pelvis 
Urine dipstick 
Mid-stream urine for culture and sensitivity 
(MSU) 
Full Blood Count  
Liver Function Tests  
Urea and Electrolytes (U&E) 
blood sugar 
Additional investigations as indicated by 
cases 
Thyroid Function Tests  
Calcium and magnesium 
Serum amylase 
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Hepatitis screening 
Renal and hepatic ultrasound 
Serum human chorionic gonadotrophin 
(HCG) 
 
The Management: 
The main objective of the treatment is to correct dehydration, prevent complications and make 
the woman feel better. Early and effective management is important. The average length of 
stay in hospital for HG is 3 to 4 days, and 25% of women with HG require readmission to 
hospital (Gadsby et al, 2011).The disease has a significant effect on the physical wellbeing of 
the woman and on her quality of life, as well as a financial impact on the health care system. 
The ambulatory treatment of nausea and vomiting of pregnancy is gaining popularity, reducing 
hospital inpatient stay and is acceptable to patients (McCarthy et al, 2014). 
The non-medical approach to the treatment of nausea and vomiting of pregnancy is 
complementary to supportive and symptomatic treatment and should not be underestimated. 
There are several natural approaches adopted by women to alleviate the symptoms with 
variable success including the avoidance of precipitating factors such as certain smells or tastes, 
eating plain food such as toast and the use of ginger (Swallow et al, 2005; Matthews et al, 2014; 
Thomson et al, 2014). There is evidence that ginger extracts can accelerate gastric emptying 
and stimulate gastric antral contraction (Giacosa et al, 2015). However, there is a paucity of 
data on the safe use of ginger in pregnancy and larger randomized controlled trials are required 
(Boltman-Binkowski, 2016). 
Reassurance and emotional support along with counselling are also recommended (RCOG, 
2016). There is presently a dearth of evidence for the use of acupuncture or hypnosis. Women 
should be informed that acupuncture is safe during pregnancy; however hypnosis is not 
recommended (RCOG, 2016). 
 
Pharmacological treatment and fluid therapy 
The majority of prescriptions for the treatment of nausea and vomiting in pregnancy, in the 
USA, are with medications not licensed for use in pregnancy, and are not specifically 
antiemetics and are not classified as safe in pregnancy (Cohen et al, 2014). 
The pharmacological treatment is generally symptomatic and supportive with antiemetics, fluid 
and electrolyte replacement, supplementation with thiamine (vitamin B1), pyridoxine (vitamin 
B6), dietary advice and prevention of venous thromboembolic disease, see Table (3). Women 
who are dehydrated and severely ketotic require hospital admission. 
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Table (3) Showing the list of medications used in the treatment of nausea and vomiting of 
early pregnancy 
 
Medication   Dose  Route of administration 
Pyridoxine (vitamin B6) 10-25 mg 8 hourly Oral 
Thiamine (vitamin B1) 75-150 mg per day Oral or Intravenous 
Cyclizine 50 mg 8 hourly Oral, Intramuscular and 
Intravenous 
Meclizine 25 mg every four to six hours Oral 
Promethazine (Phenergan) 12.5 mg to 25 mg every hours Oral, Intramuscular, 
Intravenous and Rectal 
Doxylamine 25 mg once a day Oral 
Doxylamine and pyridoxine  Doxylamine 10 mg and 
Pyridoxine 10 mg 
Oral 
Diphenhydramine Oral: 25 to 50 mg every four 
to six hours 
Intravenous: 10 to 50 mg 
every four to six hours 
Oral and Intravenous 
Metoclopramide 10 mg 8 hourly Oral, Intramuscular and 
Intravenous 
Prochlorperazine 5 mg three times a day Oral  
Droperidol 10 mg four times a day Oral  
Ondansetron 4 mg every eight hours Oral and Intravenous 
Corticosteroid: 
Hydrocortisone and 
prednisolone 
Or 
Methylprednisolone and 
prednisolone 
Initial dose 100 mg of 
Hydrocortisone 12 hourly 
followed by 40 mg of 
prednisolone once a day 
Or 
16 mg of Methylprednisolone 
every 8 hours for 48 to 72 
hours, followed by 40 mg oral 
prednisone per day for one 
day, followed by 20 mg per 
day for three days, followed 
by 10 mg per day for three 
days, and then 5 mg per day 
for seven days. 
Intravenous and Oral  
Mirtazapine 15 to 30 mg once a day Oral and Intravenous 
Ranitidine 150 mg 12 hourly Oral 
Cimetidine 200 mg once a day Oral 
Lansoprazole 30 to 40 mg once a day Oral and Intravenous 
Esomeprazole 30 to 40 mg once a day Oral and Intravenous 
Alginates combined with 
antacid (Gaviscon) 
10-20 mls 8 hourly Oral 
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Thiamine (Vitamin B1) is a water-soluble vitamin primarily absorbed in the small intestine, 
and constant supplementation is critical. Thiamine acts as a cofactor for glucose metabolism 
and in dependent areas of the brain, in particular thalami and mammillary bodies, excess 
carbohydrate causes damage leading to Wernicke’s encephalopathy, which manifests as 
confusion, ataxia and eye movement abnormalities. Treatment must be prompt with the 
immediate administration of thiamine (Giugale et al, 2015).Dextrose infusion should be 
avoided. 
All hospital units should have guidelines and protocols for the treatment of HG with thiamine 
supplementation and intravenous fluid administration, see suggested pathways (1) and (2) for 
management. 
Normal Saline is recommended with Potassium Chloride (KCl) added as indicated by Urea and 
Electrolytes (U&E) in preference to Hartmann’s or Ringer’s, as it contains a higher 
concentration of Sodium Chloride (NaCl), and care must be taken to avoid hyponatraemia, 
which can lead to central pontine myelosis. 
Double strength Saline should not be used as rapid correction of sodium depletion itself can 
cause central pontine myelosis. Thiamine can be given orally 25-50mg three times a day or 
intravenously 100mg diluted in 100 ml of Normal Saline over 60 minutes, especially, if the 
patient is on Dextrose infusion or parenteral feeding (RCOG, 2016). Treatment doses in 
established Wernicke’s are higher e.g. 500 mg twice a day (Berdai et al, 2016). 
First-line antiemetics Medications: 
Antiemetics should be offered to women whose condition does not improve after rehydration 
and correction of electrolyte imbalance. Different antiemetics have been used safely in early 
pregnancy,either singularly or in combination with no difference in efficacy (Mayhall et al, 
2015). 
Vitamin B6 or pyridoxine has an effect on nausea rather than on vomiting; however, how it 
causes its therapeutic effect remains unknown or speculative, and it may correct a deficiency 
or it may have an intrinsic anti-nausea effect, and there is no evidence that it has any adverse 
effect on the fetus (Koren et al, 2010; Nuangchamnong N, and Niebyl J, 2014). 
The antihistamines:include Cyclizine, Promethazine and Doxylamine, which are H1 receptor 
agonists have been used as first line treatment for nausea and vomiting of pregnancy with 
efficacy and good safety profile (Seto et al, 1997). There are three possible mechanisms of 
action that explain their antiemetic effect: direct inhibition of H1 receptor, indirect effect on 
the vestibular system and inhibition of the muscarinic receptor.Antihistamines however can 
cause drowsiness. 
Dopamine-receptor agonists: The antiemetic effect of these medications is via their action on 
the dopamine receptors in the stomach. The commonly used two medications 
are:Metoclopramide and Prochlorperazine. These drugs are known to potentially cause 
extrapyramidal side effects such as dystonia, dyskinesia or oculogyric crises which will require 
prompt treatment with Procyclidine 5mg intramuscular or intravenous; hence, some authorities 
recommend its use as a second-line therapy (RCOG, 2016). 
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Second-line antiemetics Medications: 
Antidopaminergic: Droperidol. There are no reported fetal congenital anomalies with its use 
in early pregnancy; however, the drug has maternal side effects including extrapyramidal 
(torsades de pointes) and cardiac (QT prolongation). 
Serotonin 5-HT receptor antagonist:Ondansetron is effective as an antiemetic; however, 
some studies have raised concerns over possible increased risk of congenital heart disease 
(Anonymous, 2015; Carstairs, 2016). Other authors however have shown a similar number of 
defects in the untreated versus Ondansetron treated groups leading them to conclude that there 
was no increased risk of teratogenicity (Fejzo et al, 2016). The numbers in all the studies were 
relatively low. A possible rare association of Ondansetron and intestinal obstruction has been 
reported(Cohen et al, 2014), and the assertion of this link has been repeated by other authors 
(Fejzo et al, 2015). Advice includes maintaining a regular bowel habit and consideration of 
stopping the drug if constipation becomes severe. Further safety studies involving greater 
numbers of patients are required. 
Severe HG management: 
Severe HG, unresponsive to conventional management is a disabling condition associated with 
prolonged and multiple admissions to hospital. It can be difficult to treat and in extreme cases 
a woman may request termination of pregnancy. In severe HG, some reports suggest that 
corticosteroid therapy may produce an improvement (Neill and Nelson-Piercy, 2003; Taylor, 
1996), but the mechanism of action of corticosteroids for the treatment of HG is unknown. This 
type of treatment should be reserved to the few cases when conventional therapies fail, and 
should be used with caution in the first trimester.An initial regimen of hydrocortisone 100mg 
twice a day followed by 40 mg prednisolone daily is recommended (Neill and Nelson-Piercy, 
2003), and should be gradually tapered down. The aim is to stop steroid treatment by 20 weeks; 
however, some patients may require them beyond this, and this can have side effect 
implications, including: osteoporosis, hip necrosis, gestational diabetes and 
immunosuppression.Long-term prednisolone use at these doses is not known to be associated 
with poor fetal outcome. If corticosteroids fail, a trial of total parenteral nutrition may be 
necessary (Subramaniam et al, 1998). At all stages, patients need psychological support, and 
physicians prescribing Total Parenteral Nutrition (TPN) for severe cases of HG must remember 
that compositions of TPN are not standardized and that Wernicke’s may develop if thiamine is 
not included (Giugale et al, 2015). 
 
Adjunctive therapy: 
Antacids with or without alginates, H2 blockers andProton Pump Inhibitors (PPI) have been 
used alone, or in combination with antiemetic therapy, for reflux oesophagitis and nausea and 
vomiting in early pregnancy with some success. They have not been associated with any 
increased risk for congenital malformations in humans despite animal evidence of arthropathy 
(Matok et al, 2012; Strugala et al 2012). H2 receptor antagonistshave also been used for reflux 
oesophagitis alone in pregnancy, with no apparent increased risk of teratogenicity, however 
patient numbers in the studies were low (Garbis et al, 2005; Magee et al, 1996), and of concern 
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is that cimetidine is known to have side effects including a risk of gynecomastia in males 
(García Rodríguez and Jick, 1994). 
Thromboprophylaxis: 
The combination of dehydration, hospitalization and pregnancy increase the risk of venous 
thromboembolic disease; hence, thromboprophylaxis by hydration, low molecular weight 
heparine.g. Enoxaparin 40mg subcutaneousdailyand mechanical means such as TED stockings 
and pneumatic cuffs is recommended, where there are no contraindications(RCOG, 2016; Neill 
and Nelson-Piercy, 2003). 
Complications: 
Complications are rare, but may develop in severe cases not responding to treatment or in 
badly-managed cases and include: 
- Haemetemesis and Mallory‐Weiss Syndrome 
- Wernicke’s encephalopathy 
- Central Pontine Myelosis 
- Electrolyte imbalance 
- Acute renal failure 
- Malnutrition and vitamin deficiency 
- VTE and Coagulopathy  
- Pneumothorax and spontaneous pneumomediastinum  
- Depression 
- Splenic avulsion 
Summary and conclusions: 
- There is a lack of high quality evidence for the management of HG in pregnancy 
- Nausea and vomiting of pregnancy is common 
- The approach to management should be systematic and holistic 
- It is important to exclude other causes of HG 
- Early supportive treatment is usually effective and reduces the risk of complications 
- Some of the non-medical remedies are effective and are favored by some women 
- Thiamine and intravenous fluids (Normal Saline) are the mainstay of therapy 
- Antihistamines and Dopamine-receptor agonists should be the first line antiemetic 
treatment 
- Corticosteroid therapy should be reserved for severe cases unresponsive to 
conventional therapy 
- Wernicke’s encephalopathy has been associated with some types of Bariatric Surgery 
and with TPN treatment, and Thiamine supplementation should not be forgotten in 
this group, particularly as there is an increasing number of pregnancies following 
Bariatric Surgery. 
 
 
 
 
EDITORIAL  
 
 
Gezira Journal Of Health Sciences 2018 vol.14(1) 
 
Gezira Journal Of Health Sciences 2018 vol.14(1) 
 
 
 
 
Pathway (1) for the management of nausea and vomiting of pregnancy# 
A woman in early pregnancy presenting with nausea and vomiting 
      
      
Comprehensive clinical evaluation in the Gynaecological Assessment unit 
      
  
Non-pregnancy causes 
       
Manage accordingly 
 
Consult and/or refer to specialist if appropriate 
          
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy related 
Full clinical examination 
Record Temperature, Pulse rate, Blood pressure 
Weigh patient 
Assess hydration 
Urine test 
FBC, U&E, LFT, 
Serum glucose level 
Pelvic ultrasound 
Other investigations 
Dehydrate
d Ketotic 
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Admit 
 
 
 
 
 
Intravenous fluids: Normal saline +/- Potassium 
Chloride 
Fluid-balance chart 
 
 
VTE prophylaxis: Ted stockings and 
LMWH    
 
 
 
 
Not dehydrated 
No ketones 
Treat and discharge with antiemetics, folic acid and thiamine 
Advise oral fluids, small frequent meals 
Avoid greasy, spicy, odorous, sugary food 
Thiamine First-line antiemetics 
Improved 
Second and third-line treatment 
No improvement 
Discharge with antiemetics, folic acid and thiamine 
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Pathway (2) for the management of nausea and vomiting of pregnancy as an outpatient# 
A woman in early pregnancy presenting with nausea and vomiting 
            
Comprehensive clinical evaluation in the Gynaecological Assessment unit 
      
 
   
    
 
  
 
 
 
 
 
   
   
     
 
 
  
    
 
 
   
  
  
 
 
Based on RCOG Guidelines, 2016 
Full clinical examination 
Record Temperature, Pulse rate, Blood pressure 
Weigh patient 
Assess hydration 
Urine test 
FBC, U&E, LFT, 
Serum glucose level 
Pelvic ultrasound 
Other investigations 
Moderate 
dehydration 
Urine ketones 1+ to 2+ Normal investigations 
Intravenous fluids: 
Normal saline 
+/- 20 mmol of Potassium Chloride 
Infuse in 2-4 hours 
First-line antiemetics Intravenous 
Thiamine 
Assess after 4-6 hours 
Improved 
Discharge with antiemetics, folic acid and thiamine No improvement 
Admit 
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Current Research Questions: 
1- What is the pathophysiology of HG? Vomiting involves an interaction of 
neurophysiological connections to the chemoreceptor trigger zone, emetic centre 
and vestibular centre in the brainstem and medulla oblongata. Further studies 
including functional MRI may help to clarify the pathophysiology. 
2- Large randomized controlled trials are required to clarify the safety and efficacy of 
the drugs used for the treatment of nausea and vomiting in pregnancy and HG. 
3- Large randomized controlled studies are required to clarify the role of acupuncture 
and hypnosis in the treatment of nausea and vomiting in pregnancy and HG. 
Self-assessment questions: 
Please answer True or False to the following statements: 
1- HG is a clearly defined medical condition 
2- HG has an adverse effect on the fetus 
3- Treatment of HG requires intravenous administration of Dextrose 
4- Corticosteroids are useful in the management of HG 
5- Wernicke’s encephalopathy is now a diagnosis of the past 
Answers: 
1- False. There is no widely accepted point at which nausea and vomiting in 
pregnancy becomes HG, nor is there any universal definition. 
2- False. There is no association with Apgar scores, congenital anomalies or 
perinatal death. Little is known about the long term health effects of babies 
born to mothers whose pregnancies were complicated by HG, however studies 
suggest that nausea and vomiting of pregnancy may be associated with a 
favorable fetal outcome. 
3- False. Thiamine acts as a cofactor for glucose metabolism and in dependent 
areas of the brain, (in particular thalami and mammillary bodies), excess 
carbohydrate causes damage leading to Wernicke’s encephalopathy, which 
manifests as confusion, ataxia and eye movement abnormalities. Treatment 
must be prompt with the immediate administration of thiamine. Dextrose 
should therefore be avoided, and nausea and vomiting must be treated with 
thiamine supplementation. Normal Saline is recommended with KCl added as 
indicated by U&E that in preference to Hartmann’s or Ringer’s, as it contains 
a higher concentration of Sodium, and care must be taken to avoid 
hyponatraemia, which can lead to central pontine myelosis. 
4- True. In women with severe HG there are data suggesting that corticosteroid 
therapy may produce an improvement. The mechanism of action of 
corticosteroids for the treatment of HG is unknown, and they are reserved 
when conventional treatment fails. 
5- False. Wernicke’s encephalopathy secondary to HG is still being reported in 
the literature, though mortalities are now rare. It has been described following 
EDITORIAL  
 
   
Gezira Journal Of Health Sciences 2018 vol.14(1) 
 
Gezira Journal Of Health Sciences 2018 vol.14(1) 
 
some types of bariatric surgery, and should be kept in mind as pregnancy 
following bariatric surgery is becoming more common. 
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